139 related articles for article (PubMed ID: 38379091)
1. Breast cancer diagnosed after age 70 years in Israeli BRCA1/BRCA2 pathogenic sequence variant carriers: a single institution experience.
Bufman H; Faermann R; Halshtok-Neiman O; Shalmon A; Gotlieb M; Samoocha D; Yagil Y; Feldman DM; Friedman E; Sklair-Levy M
Breast Cancer Res Treat; 2024 Jun; 205(2):281-285. PubMed ID: 38379091
[TBL] [Abstract][Full Text] [Related]
2. Pregnancy Associated Breast Cancer Among Israeli BRCA1/BRCA2 Carriers in a High-Risk Clinic.
Faermann R; Friedman E; Kaidar-Person O; Brodsky M; Neiman OH; Shalmon A; Gotlieb M; Yagil Y; Samocha D; Feldman DM; Weidenfeld J; Sklair-Levy M
Acad Radiol; 2023 Feb; 30(2):248-254. PubMed ID: 35527100
[TBL] [Abstract][Full Text] [Related]
3. Ductal Carcinoma In Situ (DCIS) Diagnosed by MRI-Guided Biopsy among
Faermann R; Friedman E; Kaidar-Person O; Weidenfeld J; Brodsky M; Shalmon A; Halshtok Neiman O; Gotlieb M; Yagil Y; Samoocha D; Madorsky Feldman D; Sklair-Levy M
Breast J; 2022; 2022():4317693. PubMed ID: 36349178
[TBL] [Abstract][Full Text] [Related]
4. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
5. Abnormal Findings Detected by Multi-modality Breast Imaging and Biopsy Results in a High-risk Clinic.
Laitman Y; Feldman DM; Sklair-Levy M; Yosepovich A; Barshack-Nakar I; Brodsky M; Halshtok O; Shalmon A; Gotlieb M; Friedman E
Clin Breast Cancer; 2018 Aug; 18(4):e695-e698. PubMed ID: 29292184
[TBL] [Abstract][Full Text] [Related]
6. Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers-an Israeli matched-pair study.
Perri T; Levin G; Naor-Revel S; Eliassi-Revivo P; Lifshitz D; Friedman E; Korach J
Int J Gynaecol Obstet; 2022 May; 157(2):431-436. PubMed ID: 34324701
[TBL] [Abstract][Full Text] [Related]
7. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
Bernholtz S; Laitman Y; Kaufman B; Shimon-Paluch S; Friedman E
Breast Cancer Res Treat; 2012 Apr; 132(2):669-73. PubMed ID: 22113258
[TBL] [Abstract][Full Text] [Related]
8. [GENOTYPE-PHENOTYPE CORRELATIONS BY SPECIFIC FOUNDER VARIANTS IN BRCA IN ISRAELI WOMEN].
Michaelson-Cohen R; Laitman Y; Kedar I; Baris-Feldman H; Reish O; Lieberman S; Bernstein-Molho R; Goldberg Y; Reznick Levi G; Gershoni R; Beller U; Levy-Lahad E; Catan R; Friedman E
Harefuah; 2023 Jun; 162(6):370-375. PubMed ID: 37394440
[TBL] [Abstract][Full Text] [Related]
9. Post-mastectomy surveillance of BRCA1/BRCA2 mutation carriers: Outcomes from a specialized clinic for high-risk breast cancer patients.
Kanana N; Ben David MA; Nissan N; Yagil Y; Shalmon A; Halshtok O; Gotlieb M; Faermann R; Klang E; Samoocha D; Yassin M; Davidson T; Zippel D; Madorsky Feldman D; Friedman E; Kaidar-Person O; Sklair Levy M
Breast J; 2021 May; 27(5):441-447. PubMed ID: 33576117
[TBL] [Abstract][Full Text] [Related]
10. Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
Shimada S; Yoshida R; Nakashima E; Kitagawa D; Gomi N; Horii R; Takeuchi S; Ashihara Y; Kita M; Akiyama F; Ohno S; Saito M; Arai M
Breast Cancer; 2019 Nov; 26(6):846-851. PubMed ID: 30980249
[TBL] [Abstract][Full Text] [Related]
11. The yield of full BRCA1/2 genotyping in Israeli Arab high-risk breast/ovarian cancer patients.
Bernstein-Molho R; Barnes-Kedar I; Ludman MD; Reznik G; Feldman HB; Samra NN; Eilat A; Peretz T; Peretz LP; Shapira T; Magal N; Kalis ML; Yerushalmi R; Vinkler C; Liberman S; Basel-Salmon L; Shohat M; Levy-Lahad E; Friedman E; Bazak L; Goldberg Y
Breast Cancer Res Treat; 2019 Nov; 178(1):231-237. PubMed ID: 31368036
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer screening in BRCA1/2 pathogenic sequence variant carriers during pregnancy and lactation.
Sorin V; Bufman H; Bernstein-Molho R; Faermann R; Friedman E; Raskin D; Balint Lahat N; Sklair-Levy M
Clin Imaging; 2024 Jul; 111():110189. PubMed ID: 38759599
[TBL] [Abstract][Full Text] [Related]
13. Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers.
Galmor L; Bernstein-Molho R; Sklair-Levy M; Madoursky-Feldman D; Zippel D; Laitman Y; Friedman E
Breast Cancer Res Treat; 2021 Jan; 185(2):391-399. PubMed ID: 33000375
[TBL] [Abstract][Full Text] [Related]
14. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
Giannakeas V; Lubinski J; Gronwald J; Moller P; Armel S; Lynch HT; Foulkes WD; Kim-Sing C; Singer C; Neuhausen SL; Friedman E; Tung N; Senter L; Sun P; Narod SA
Breast Cancer Res Treat; 2014 Aug; 147(1):113-8. PubMed ID: 25082516
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
[TBL] [Abstract][Full Text] [Related]
16. Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in
Guindalini RSC; Zheng Y; Abe H; Whitaker K; Yoshimatsu TF; Walsh T; Schacht D; Kulkarni K; Sheth D; Verp MS; Bradbury AR; Churpek J; Obeid E; Mueller J; Khramtsova G; Liu F; Raoul A; Cao H; Romero IL; Hong S; Livingston R; Jaskowiak N; Wang X; Debiasi M; Pritchard CC; King MC; Karczmar G; Newstead GM; Huo D; Olopade OI
Clin Cancer Res; 2019 Mar; 25(6):1786-1794. PubMed ID: 30154229
[TBL] [Abstract][Full Text] [Related]
17. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
Michaelson-Cohen R; Gabizon-Peretz S; Armon S; Srebnik-Moshe N; Mor P; Tomer A; Levy-Lahad E; Paluch-Shimon S
Eur J Cancer; 2021 May; 148():95-102. PubMed ID: 33743487
[TBL] [Abstract][Full Text] [Related]
19. Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography.
van Zelst JCM; Mus RDM; Woldringh G; Rutten MJCM; Bult P; Vreemann S; de Jong M; Karssemeijer N; Hoogerbrugge N; Mann RM
Radiology; 2017 Nov; 285(2):376-388. PubMed ID: 28609204
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer surveillance for BRCA1/2 mutation carriers - is "early detection" early enough?
Bernstein-Molho R; Kaufman B; Ben David MA; Sklair-Levy M; Feldman DM; Zippel D; Laitman Y; Friedman E
Breast; 2020 Feb; 49():81-86. PubMed ID: 31760168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
